|
1
|
Nooreldeen R and Bach H: Current and
future development in lung cancer diagnosis. Int J Mol Sci.
22:86612021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu F, Wang L and Zhou C: Lung cancer in
China: Current and prospect. Curr Opin Oncol. 33:40–46. 2021.
View Article : Google Scholar
|
|
3
|
Teramoto K, Ozaki Y, Hanaoka J, Sawai S,
Tezuka N, Fujino S, Daigo Y and Kontani K: Predictive biomarkers
and effectiveness of MUC1-targeted dendritic-cell-based vaccine in
patients with refractory non-small cell lung cancer. Ther Adv Med
Oncol. 9:147–157. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun M, Shi Y, Dang UJ and Di Pasqua AJ:
Phenethyl isothiocyanate and cisplatin co-encapsulated in a
liposomal nanoparticle for treatment of non-small cell lung cancer.
Molecules. 24:8012019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Y, Qian J, Yang M, Xu W, Wang J, Hou
G, Ji L and Suo A: Doxorubicin/cisplatin co-loaded hyaluronic
acid/chitosan-based nanoparticles for in vitro synergistic
combination chemotherapy of breast cancer. Carbohydr Polym.
225:1152062019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nasrollahi F, Koh YR, Chen P, Varshosaz J,
Khodadadi AA and Lim S: Targeting graphene quantum dots to
epidermal growth factor receptor for delivery of cisplatin and
cellular imaging. Mater Sci Eng C Mater Biol Appl. 94:247–257.
2019. View Article : Google Scholar
|
|
7
|
Gualdani R, de Clippele M, Ratbi I, Gailly
P and Tajeddine N: Store-operated calcium entry contributes to
cisplatin-induced cell death in non-small cell lung carcinoma.
Cancers (Basel). 11:4302019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ashique S, Sandhu NK, Chawla V and Chawla
PA: Targeted drug delivery: Trends and perspectives. Curr Drug
Deliv. 18:1435–1455. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tavakkoli Yaraki M, Daqiqeh Rezaei S and
Tan YN: Simulation guided design of silver nanostructures for
plasmon-enhanced fluorescence, singlet oxygen generation and SERS
applications. Phys Chem Chem Phys. 22:5673–5687. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sarfaraz N and Khan I: Plasmonic gold
nanoparticles (AuNPs): Properties, synthesis and their advanced
energy, environmental and biomedical applications. Chem Asian J.
16:720–742. 2021. View Article : Google Scholar
|
|
11
|
Mittal D, Singh A, Kohli K and Verma AK:
Engineering biosafe cisplatin loaded nanostructured lipid carrier:
Optimisation, synthesis, pharmacokinetics and biodistribution. J
Microencapsul. 39:522–538. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herrera-Juarez M, Serrano-Gomez C,
Bote-de-Cabo H and Paz-Ares L: Targeted therapy for lung cancer:
Beyond EGFR and ALK. Cancer. 129:1803–1820. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moosavian SA, Abnous K, Akhtari J, Arabi
L, Gholamzade Dewin A and Jafari M: 5TR1 aptamer-PEGylated
liposomal doxorubicin enhances cellular uptake and suppresses
tumour growth by targeting MUC1 on the surface of cancer cells.
Artif Cells Nanomed Biotechnol. 46:2054–2065. 2018.
|
|
14
|
Noble GT, Stefanick JF, Ashley JD,
Kiziltepe T and Bilgicer B: Ligand-targeted liposome design:
Challenges and fundamental considerations. Trends Biotechnol.
32:32–45. 2014. View Article : Google Scholar
|
|
15
|
Filipczak N, Pan J, Yalamarty SSK and
Torchilin VP: Recent advancements in liposome technology. Adv Drug
Deliv Rev. 156:4–22. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saw PE, Park J, Lee E, Ahn S, Lee J, Kim
H, Kim J, Choi M, Farokhzad OC and Jon S: Effect of PEG pairing on
the efficiency of cancer-targeting liposomes. Theranostics.
5:746–754. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Underwood C, van Eps AW, Ross MW, Laverman
P, van Bloois L, Storm G and Schaer TP: Intravenous technetium-99m
labelled PEG-liposomes in horses: A safety and biodistribution
study. Equine Vet J. 44:196–202. 2012. View Article : Google Scholar
|
|
18
|
Namba M, Hattori N, Hamada H, Yamaguchi K,
Okamoto Y, Nakashima T, Masuda T, Sakamoto S, Horimasu Y, Miyamoto
S, et al: Anti-KL-6/MUC1 monoclonal antibody reverses resistance to
trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity
by capping MUC1. Cancer Lett. 442:31–39. 2019. View Article : Google Scholar
|
|
19
|
Bouillez A, Adeegbe D, Jin C, Hu X, Tagde
A, Alam M, Rajabi H, Wong KK and Kufe D: MUC1-C promotes the
suppressive immune microenvironment in non-small cell lung cancer.
Oncoimmunology. 6:e13389982017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kumar P, Lindberg L, Thirkill TL, Ji JW,
Martsching L and Douglas GC: The MUC1 extracellular domain subunit
is found in nuclear speckles and associates with spliceosomes. PLoS
One. 7:e427122012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beack S, Cho M, Kim YE, Ahn GO and Hahn
SK: Hyaluronate-peanut agglutinin conjugates for target-specific
bioimaging of colon cancer. Bioconjug Chem. 28:1434–1442. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu X, McFall-Boegeman H, Rashidijahanabad
Z, Liu K, Pett C, Yu J, Schorlemer M, Ramadan S, Behren S,
Westerlind U and Huang X: Synthesis and immunological evaluation of
the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate. Org
Biomol Chem. 19:2448–2455. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li X, Diao W, Xue H, Wu F, Wang W, Jiang
B, Bai J, Lian B, Feng W, Sun T, et al: Improved efficacy of
doxorubicin delivery by a novel dual-ligand-modified liposome in
hepatocellular carcinoma. Cancer Lett. 489:163–173. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zahednezhad F, Zakeri-Milani P, Shahbazi
Mojarrad J and Valizadeh H: The latest advances of cisplatin
liposomal formulations: essentials for preparation and analysis.
Expert Opin Drug Deliv. 17:523–541. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Long DF and Repta AJ: Cisplatin:
Chemistry, distribution and biotransformation. Biopharm Drug
Dispos. 2:1–16. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng Y, Zhao P, Wu S, Yang T, Chen Y,
Zhang X, He C, Zheng C, Li K, Ma X and Xiang G: Cisplatin and
curcumin co-loaded nano-liposomes for the treatment of
hepatocellular carcinoma. Int J Pharm. 545:261–273. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saracchini S, Foltran L, Tuccia F, Bassini
A, Sulfaro S, Micheli E, Del Conte A, Bertola M, Gion M, Lorenzon M
and Tumolo S: Phase II study of liposome-encapsulated doxorubicin
plus cyclophosphamide, followed by sequential trastuzumab plus
docetaxel as primary systemic therapy for breast cancer patients
with HER2 overexpression or amplification. Breast. 22:1101–1107.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Wu H, Shen H, Geng S, Wang B, Wang
Y, Ma X, Li G and Tan M: A bimodal MRI and NIR liposome nanoprobe
for tumor targeted molecular imaging. J Mater Chem B. 3:8832–8841.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Theodosiou M, Sakellis E, Boukos N,
Kusigerski V, Kalska-Szostko B and Efthimiadou E: Iron oxide
nanoflowers encapsulated in thermosensitive fluorescent liposomes
for hyperthermia treatment of lung adenocarcinoma. Sci Rep.
12:86972022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang X, Lü S, Han J, Sun S, Wang L and Li
Y: Preparation, characterization and in vivo distribution of solid
lipid nanoparticles loaded with syringopicroside. Pharmazie.
66:404–407. 2011.PubMed/NCBI
|
|
31
|
Lippard SJ: New chemistry of an old
molecule: Cis-[Pt(NH3)2Cl2]. Science. 218:1075–1082. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Newman MS, Colbern GT, Working PK, Engbers
C and Amantea MA: Comparative pharmacokinetics, tissue
distribution, and therapeutic effectiveness of cisplatin
encapsulated in long-circulating, pegylated liposomes (SPI-077) in
tumor-bearing mice. Cancer Chemother Pharmacol. 43:1–7. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Diao W, Yang B, Sun S, Wang A, Kou R, Ge
Q, Shi M, Lian B, Sun T, Wu J, et al: PNA-modified liposomes
improve the delivery efficacy of CAPIRI for the synergistic
treatment of colorectal cancer. Front Pharmacol. 13:8931512022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bar J, Ofek E, Barshack I, Gottfried T,
Zadok O, Kamer I, Urban D, Perelman M and Onn A: Transformation to
small cell lung cancer as a mechanism of resistance to
immunotherapy in non-small cell lung cancer. Lung Cancer.
138:109–115. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Riaz SP, Lüchtenborg M, Coupland VH,
Spicer J, Peake MD and Møller H: Trends in incidence of small cell
lung cancer and all lung cancer. Lung Cancer. 75:280–284. 2012.
View Article : Google Scholar
|
|
37
|
Zhong WZ, Yan HH, Chen KN, Chen C, Gu CD,
Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, et al: Erlotinib versus
gemcitabine plus cisplatin as neoadjuvant treatment of stage
IIIA-N2 EGFR-mutant non-small-cell lung cancer: Final overall
survival analysis of the EMERGING-CTONG 1103 randomised phase II
trial. Signal Transduct Target Ther. 8:762023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stinchcombe TE: Flashback foreword:
Cisplatin/pemetrexed in non-small-cell lung cancer. J Clin Oncol.
41:2455–2456. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Makwana V, Karanjia J, Haselhorst T,
Anoopkumar-Dukie S and Rudrawar S: Liposomal doxorubicin as
targeted delivery platform: Current trends in surface
functionalization. Int J Pharm. 593:1201172021. View Article : Google Scholar
|
|
40
|
Lozano N, Al-Ahmady ZS, Beziere NS,
Ntziachristos V and Kostarelos K: Monoclonal antibody-targeted
PEGylated liposome-ICG encapsulating doxorubicin as a potential
theranostic agent. Int J Pharm. 482:2–10. 2015. View Article : Google Scholar
|
|
41
|
Kim DM, Kim M, Park HB, Kim KS and Kim DE:
Anti-MUC1/CD44 dual-aptamer-conjugated liposomes for cotargeting
breast cancer cells and cancer stem cells. ACS Appl Bio Mater.
2:4622–4633. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Panchamoorthy G, Jin C, Raina D, Bharti A,
Yamamoto M, Adeebge D, Zhao Q, Bronson R, Jiang S, Li L, et al:
Targeting the human MUC1-C oncoprotein with an antibody-drug
conjugate. JCI Insight. 3:e998802018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ranjbar-Navazi Z, Fathi M, Abdolahinia ED,
Omidi Y and Davaran S: MUC-1 aptamer conjugated InP/ZnS quantum
dots/nanohydrogel fluorescent composite for mitochondria-mediated
apoptosis in MCF-7 cells. Mater Sci Eng C Mater Biol Appl.
118:1114692021. View Article : Google Scholar
|
|
44
|
Marzban E, Alavizadeh SH, Ghiadi M,
Khoshangosht M, Khashayarmanesh Z, Abbasi A and Jaafari MR:
Optimizing the therapeutic efficacy of cisplatin PEGylated
liposomes via incorporation of different DPPG ratios: In vitro and
in vivo studies. Colloids Surf B Biointerfaces. 136:885–891. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zia MK, Siddiqui T, Ali SS, Rehman AA,
Ahsan H and Khan FH: Chemotherapeutic drugs and plasma proteins:
Exploring new dimensions. Curr Protein Pept Sci. 19:937–947. 2018.
View Article : Google Scholar
|
|
46
|
Romani AMP: Cisplatin in cancer treatment.
Biochem Pharmacol. 206:1153232022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li Z, Yang D, Guo T and Lin M: Advances in
MUC1-mediated breast cancer immunotherapy. Biomolecules.
12:9522022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Crinò L, Calandri C, Maestri A and
Marrocolo F: Gemcitabine and cisplatin combination in early-stage
non-small-cell lung cancer. Oncology (Williston Park). 15(3 Suppl
6): S40–S42. 2001.
|
|
49
|
Cui Z, Li D, Zhao J and Chen K: Falnidamol
and cisplatin combinational treatment inhibits non-small cell lung
cancer (NSCLC) by targeting DUSP26-mediated signal pathways. Free
Radic Biol Med. 183:106–124. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Daponte A, Ascierto PA, Gravina A, Melucci
M, Scala S, Ottaiano A, Simeone E, Palmieris G and Comella G:
Temozolomide and cisplatin in avdanced malignant melanoma.
Anticancer Res. 25:1441–1447. 2005.PubMed/NCBI
|
|
51
|
Christodoulou C, Bafaloukos D, Linardou H,
Aravantinos G, Bamias A, Carina M, Klouvas G and Skarlos D;
Hellenic Cooperative Oncology Group: Temozolomide (TMZ) combined
with cisplatin (CDDP) in patients with brain metastases from solid
tumors: A hellenic cooperative oncology group (HeCOG) phase II
study. J Neurooncol. 71:61–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bafaloukos D, Tsoutsos D, Kalofonos H,
Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E,
Polyzos A and Fountzilas G: Temozolomide and cisplatin versus
temozolomide in patients with advanced melanoma: A randomized phase
II study of the Hellenic cooperative oncology group. Ann Oncol.
16:950–957. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Weed DT, Zilio S, Reis IM, Sargi Z,
Abouyared M, Gomez-Fernandez CR, Civantos FJ, Rodriguez CP and
Serafini P: The reversal of immune exclusion mediated by tadalafil
and an anti-tumor vaccine also induces PDL1 Upregulation in
recurrent head and neck squamous cell carcinoma: interim analysis
of a phase I clinical trial. Front Immunol. 10:12062019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ishida S, Lee J, Thiele DJ and Herskowitz
I: Uptake of the anticancer drug cisplatin mediated by the copper
transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA.
99:14298–14302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Akhter J, Goswami P, Ali Beg MM, Ahmad S,
Najmi AK and Raisuddin S: Protective effect of rosmarinic acid on
the transmembrane transporter Ctr1 expression in cisplatin-treated
mice. J Cancer Res Ther. 19:1753–1759. 2023. View Article : Google Scholar
|
|
56
|
Huang CP, Fofana M, Chan J, Chang CJ and
Howell SB: Copper transporter 2 regulates intracellular copper and
sensitivity to cisplatin. Metallomics. 6:654–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Akerfeldt MC, Tran CMN, Shen C, Hambley TW
and New EJ: Interactions of cisplatin and the copper transporter
CTR1 in human colon cancer cells. J Biol Inorg Chem. 22:765–774.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang P, Li B, Chen Q, Wang H and Feng Q:
Glucose restriction induces ROS-AMPK-mediated CTR1 expression and
increases cisplatin efficiency in NSCLC. Cancer Lett.
543:2157932022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ishida T, Harashima H and Kiwada H:
Liposome clearance. Biosci Rep. 22:197–224. 2002. View Article : Google Scholar : PubMed/NCBI
|
